Deliver eSight® To Your Patients via Telehealth
eSight is a clinically validated, FDA-registered low vision device designed to help your patients with central vision loss achieve up to 20/20 visual acuity.
eSight® – A proven low vision device for your patients with central vision loss
eSight enables patients with central vision loss to achieve up to 20/20 visual acuity. It works by stimulating the synaptic nerve activity in the remaining photoreceptor function in the patient’s eyes to provide increased visual information to the brain. In doing so, eSight delivers life-changing results for thousands of people with macular degeneration, diabetic retinopathy, Stargardt disease and more.
eSight provides unprecedented improvement in a wide range of visual performance measures for patients with one of over 20 different eye conditions associated with central vision loss.¹ eSight is a class 1 medical device that is registered with the FDA and EUDAMED, and inspected by Health Canada.
eSight® Is Clinically Validated Through A Peer-Reviewed Multicenter Trial
A multisite, prospective, single-arm study that involved six recruitment centers investigated the short-and medium-term effects of eSight. With a sample size of n=51, this study primarily demonstrated:
- A seven-line gain in distance acuity
- 100% mobility retention
- 12 letter contrast improvement
- Improvement in critical print size and reading acuity
- Significant increase in facial recognition
eSight eyewear significantly improves distance acuity
Figure 1. Distance acuity equivalent of print size correctly read on the ETDRS chart at baseline without the device, at fitting with the device, and after 3 months of device use. Mean baseline acuity without device was 20/177 (mean logMAR, 0.95 [SD, 0.25]), which improved to 20/32 (mean, 0.20 [SD, 0.31]) with the device but stayed unchanged after 3 months of device use and training (mean, 0.19 [SD, 0.30]). *Statistically significant differences. ETDRS = Early Treatment Diabetic Retinopathy Study.
eSight eyewear significantly improves reading acuity
Figure 2. Reading acuity equivalent of print size read on the MNREAD chart at baseline without the device, at fitting with the device, and after 3 months of device use. Mean baseline reading acuity without device was 20/159 (mean logMAR, 0.90 [SD, 0.34]), which improved to 20/43 (mean, 0.33 [SD, 0.39]) with the device but stayed unchanged after 3 months of device use and training (mean, 0.24 [SD, 0.36]). *Statistically significant differences.
Our eQuest Partners
Experience The Ease Of eSight TeleHealth
Refer your patients to eSight Telehealth, and eSight specialists will ensure eligibility through an in-home evaluation of the device via TeleHealth. With the support of the TeleHealth training programs, eSight is efficient, reduces travel time, and offers a seamless, patient-centered experience from referral to usage.
- An appointment with an eSight clinical specialist who will train and guide patients on using the device
- The use of an eSight device for several days for evaluation after the training session
- No cost or financial obligation to the patient with your referral
Testimonials
User Stories
Laney Avoids Assisted Living With eSight
Meet Laney from Jacksonville, Florida who diagnosed macular degeneration and glaucoma. Life and word before eSight Doctors told Laney in 2011 that she had Macular Degeneration & Glaucoma, she...
CEO Brewmaster Goes Back To Work With Enhanced Vision Technology from eSight
Meet Hunter Dodge from Kalamazoo, Michigan who was diagnosed with Diabetic Retinopathy. Life and word before eSight Hunter Dodge is the CEO and President of American Brewers in Kalamazoo,...
Rhylee Hinkle Regaining her Independence with eSight
Rhylee Hinkle, 12 years old, is a student diagnosed with nystagmus, optic atrophy, cortical visual impairment, strabismus, homonymous hemianopsia, and amblyopia. Life before eSight The first...
